Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
MYSM1 maintains ribosomal protein gene expression in hematopoietic stem cells to prevent hematopoietic dysfunction
Jad I. Belle, HanChen Wang, Amanda Fiore, Jessica C. Petrov, Yun Hsiao Lin, Chu-Han Feng, Thi Tuyet Mai Nguyen, Jacky Tung, Philippe M. Campeau, Uta Behrends, Theresa Brunet, Gloria Sarah Leszinski, Philippe Gros, David Langlais, Anastasia Nijnik
Jad I. Belle, HanChen Wang, Amanda Fiore, Jessica C. Petrov, Yun Hsiao Lin, Chu-Han Feng, Thi Tuyet Mai Nguyen, Jacky Tung, Philippe M. Campeau, Uta Behrends, Theresa Brunet, Gloria Sarah Leszinski, Philippe Gros, David Langlais, Anastasia Nijnik
View: Text | PDF
Research Article Hematology Stem cells

MYSM1 maintains ribosomal protein gene expression in hematopoietic stem cells to prevent hematopoietic dysfunction

  • Text
  • PDF
Abstract

Ribosomopathies are congenital disorders caused by mutations in the genes encoding ribosomal and other functionally related proteins. They are characterized by anemia, other hematopoietic and developmental abnormalities, and p53 activation. Ribosome assembly requires coordinated expression of many ribosomal protein (RP) genes; however, the regulation of RP gene expression, especially in hematopoietic stem cells (HSCs), remains poorly understood. MYSM1 is a transcriptional regulator essential for HSC function and hematopoiesis. We established that HSC dysfunction in Mysm1 deficiency is driven by p53; however, the mechanisms of p53 activation remained unclear. Here, we describe the transcriptome of Mysm1-deficient mouse HSCs and identify MYSM1 genome-wide DNA binding sites. We establish a direct role for MYSM1 in RP gene expression and show a reduction in protein synthesis in Mysm1–/– HSCs. Loss of p53 in mice fully rescues Mysm1–/– anemia phenotype but not RP gene expression, indicating that RP gene dysregulation is a direct outcome of Mysm1 deficiency and an upstream mediator of Mysm1–/– phenotypes through p53 activation. We characterize a patient with a homozygous nonsense MYSM1 gene variant, and we demonstrate reduced protein synthesis and increased p53 levels in patient hematopoietic cells. Our work provides insights into the specialized mechanisms regulating RP gene expression in HSCs and establishes a common etiology of MYSM1 deficiency and ribosomopathy syndromes.

Authors

Jad I. Belle, HanChen Wang, Amanda Fiore, Jessica C. Petrov, Yun Hsiao Lin, Chu-Han Feng, Thi Tuyet Mai Nguyen, Jacky Tung, Philippe M. Campeau, Uta Behrends, Theresa Brunet, Gloria Sarah Leszinski, Philippe Gros, David Langlais, Anastasia Nijnik

×

Figure 1

RNA-Seq analysis of the transcriptome of Mysm1-deficient HSC and MPP cells.

Options: View larger image (or click on image) Download as PowerPoint
RNA-Seq analysis of the transcriptome of Mysm1-deficient HSC and MPP cel...
(A) Schematic representation of the inducible Mysm1-deletion model in mice and the gating strategies for HSC, MPP1, and MPP2 cells. The KO group is composed of Mysm1fl/fl CreERT2 mice following tamoxifen-induced Mysm1 deletion. The WT group is composed of tamoxifen-treated Mysm1fl/+ CreERT2 and corn-oil vehicle-treated Mysm1fl mice. (B) Partial Least Square Regression graph demonstrates the gene expression profiles of each RNA-Seq sample: differences between cell types are described by principal component 1 (PC1, 42.6% variability) and differences between genotypes by PC2 (12% variability). (C) Fold changes of 702 significantly dysregulated genes in Mysm1-deficient HSCs and MPPs. (D) Normalized enrichment scores (NES) of 4437 preestablished biological processes expression signatures used in the Gene Set Enrichment Analysis. (E) Heatmap displaying 702 significantly dysregulated genes when comparing KO with WT expression levels. The significance threshold is fold change ≥ 1.5 and FDR ≤ 0.01. Relative expressions to the average of HSC WT group are used to generate the heatmap. Hierarchical Clustering (HCL) of the genes is performed, using Pearson correlation and average linkage, to generate the 4 gene clusters. (F) Gene ontology (GO) enrichment analysis on genes from the 4 clusters described in E. Top 4 enriched biological processes terms are displayed.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts